These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29961546)

  • 1. An analysis of Drug Survival, Effectiveness, and Safety in Moderate to Severe Psoriasis Treated With Ustekinumab: An Observational Study of 69 Patients in Routine Clinical Practice.
    Salgüero Fernández I; Gil MH; Sanz MS; Gullón GR
    Actas Dermosifiliogr (Engl Ed); 2019 Apr; 110(3):244-246. PubMed ID: 29961546
    [No Abstract]   [Full Text] [Related]  

  • 2. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.
    Fioranelli M; Roccia MG; Lotti T
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28508536
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period.
    Megna M; Napolitano M; Balato N; Monfrecola G; Villani A; Ayala F; Balato A
    Clin Exp Dermatol; 2016 Jul; 41(5):564-6. PubMed ID: 27028505
    [No Abstract]   [Full Text] [Related]  

  • 4. Absolute Versus Relative Psoriasis Area and Severity Index in Clinical Practice.
    Del Alcázar Viladomiu E; Lamas Doménech N; Salleras Redonnet M
    Actas Dermosifiliogr (Engl Ed); 2019 Sep; 110(7):606-610. PubMed ID: 30803689
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety of ustekinumab in severe psoriasis with chronic hepatitis B.
    Raymundo AR; Facin AP; Silva de Castro CC; Faria AR
    Indian J Dermatol Venereol Leprol; 2016; 82(3):326-8. PubMed ID: 27088944
    [No Abstract]   [Full Text] [Related]  

  • 6. Ustekinumab for the treatment of psoriasis: an evidence update.
    Yiu ZZ; Warren RB
    Semin Cutan Med Surg; 2018 Sep; 37(3):143-147. PubMed ID: 30215630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
    Phan C; Beauchet A; Burztejn AC; Severino-Freire M; Barbarot S; Girard C; Lasek A; Reguiai Z; Hadj-Rabia S; Abasq C; Brenaut E; Droitcourt C; Perrussel M; Mallet S; Phan A; Lacour JP; Khemis A; Bourrat E; Chaby G; Deborde R; Plantin P; Maruani A; Piram M; Maccari F; Fougerousse AC; Kupfer-Bessaguet I; Balguérie X; Barthelemy H; Martin L; Quiles-Tsimaratos N; Mery-Brossard L; Pallure V; Lons-Danic D; Bouilly-Auvray D; Beylot-Barry M; Puzenat E; Aubin F; Mahé E; ;
    J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
    Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
    J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab.
    Čarija A; Ivić I; Marasović-Krstulović D; Puizina-Ivić N
    Rheumatology (Oxford); 2015 Nov; 54(11):2114-6. PubMed ID: 26242857
    [No Abstract]   [Full Text] [Related]  

  • 10. Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab.
    Hesselvig JH; Egeberg A; Loft ND; Zachariae C; Kofoed K; Skov L
    Acta Derm Venereol; 2018 Mar; 98(3):335-339. PubMed ID: 29110019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Worsening of Psoriatic Arthritis After Ustekinumab Treatment.
    Onsun N; Yalcin B; Sallahoglu K; Rezvani A
    Am J Ther; 2018; 25(3):e381-e382. PubMed ID: 29189317
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe dilated cardiomyopathy induced by adalimumab and ustekinumab.
    Membrillo de Novales FJ; Ávila Jiménez A; Merino Meléndez L; Torres León J; López Soberón E; Fe Marqués A; Pérez Mochales JF
    J Clin Rheumatol; 2015 Apr; 21(3):171-3. PubMed ID: 25807103
    [No Abstract]   [Full Text] [Related]  

  • 13. Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis.
    Pescitelli L; Dini V; Gisondi P; Loconsole F; Piaserico S; Piccirillo A; Stinco G; Errichetti E; Talamonti M; Tripo L; Volpi W; Prignano F
    J Dermatol Sci; 2015 May; 78(2):149-51. PubMed ID: 25681953
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety of ustekinumab for the treatment of psoriasis vulgaris with myotonic dystrophy.
    Fujita Y; Shinkuma S; Nomura T; Shimizu H
    Eur J Dermatol; 2016 Apr; 26(2):187-8. PubMed ID: 26643260
    [No Abstract]   [Full Text] [Related]  

  • 15. Liver Injury in Psoriasis Patients Receiving Ustekinumab: A Retrospective Study of 44 Patients Treated in the Clinical Practice Setting.
    Llamas-Velasco M; Concha-Garzón MJ; García-Diez A; Daudén E
    Actas Dermosifiliogr; 2015; 106(6):470-6. PubMed ID: 25912374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ustekinumab treatment in patients with psoriasis undergoing hemodialysis.
    Umezawa Y; Hayashi M; Kikuchi S; Fukuchi O; Yanaba K; Ito T; Asahina A; Saeki H; Nakagawa H
    J Dermatol; 2015 Jul; 42(7):731-4. PubMed ID: 25959602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psoriasis vulgaris complicated by eosinophilic pneumonia during ustekinumab treatment.
    Yashiro M; Maejima H; Taniguchi T; Katsuoka K; Kimura M; Wada M
    Eur J Dermatol; 2013; 23(3):396-7. PubMed ID: 23728153
    [No Abstract]   [Full Text] [Related]  

  • 18. Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study.
    Del Alcázar E; Ferran M; López-Ferrer A; Notario J; Vidal D; Riera J; Aparicio G; Gallardo F; Vilarrasa E; Alsina M; Puig L; Ferrándiz C; Carrascosa JM
    J Dermatolog Treat; 2020 May; 31(3):222-226. PubMed ID: 30883242
    [No Abstract]   [Full Text] [Related]  

  • 19. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in a solid organ transplanted recipient: A case report.
    Richetta A; Marraffa F; Grassi S; Aquila E; Dybala A; Aprile F; Merli M
    Australas J Dermatol; 2021 Aug; 62(3):e442-e443. PubMed ID: 33634474
    [No Abstract]   [Full Text] [Related]  

  • 20. Ustekinumab treatment for moderate to severe psoriasis. Eight-year real-world follow-up of 61 cases in a tertiary level hospital.
    Elberdín L; Fernández-Torres R; Paradela S; Blanco E; Outeda M; Martín I; Fonseca E
    J Dermatolog Treat; 2020 Nov; 31(7):698-701. PubMed ID: 30961404
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.